Efficacy and safety of triple wavelength laser hair reduction in skin types IV to V

J Cosmet Dermatol. 2021 Apr;20(4):1117-1123. doi: 10.1111/jocd.13995. Epub 2021 Feb 22.


Background: Laser hair reduction is one of the most common laser procedures in dermatology. Laser systems available are Ruby at 694 nm, Alexandrite (755 nm), Diode (810nm), and Nd:YAG (1064 nm). Recently, devices presenting a combination of wavelengths have shown to produce high effective hair reduction with no related risks. This study was conducted with the Soprano Ice Platinum (Alma Lasers, GMBH, Germany) that emits a combination of three wavelengths at 755, 810, and 1064 nm in a single pulse.

Aims: To establish the efficacy and safety of novel triple wavelength laser hair reduction technology in skin types IV to V.

Patients and methods: This was an investigator initiated, single-center, prospective clinical study conducted between December 2017 and June 2019 with a total of 25 patients (23 female and two male) above 18 years with skin types IV and V, areas included are face, beard, neck, chest, and others.

Results: Hair reduction was assessed using the physician GAIS (global esthetic improvement scale) score: no results 0% reduction, poor 0%-25% reduction, average 25%-50%, good 50%-75%, and excellent 75%-100%. All 25 patients (mean age 28 years, range 18-52 y/o) completed all six sessions of the study.

Conclusion: Objective clinical assessment of hair reduction using the physician GAIS score in 90 anatomical sites scores an excellent reduction in 95.5% areas and good reduction in 80% areas. This current study shows that a synergistic combination of three diode laser wavelengths used for hair removal (755, 810, 1064 nm) is effective and safe to use in subjects skin types IV and V for facial and body hair.

Keywords: in-motion triple wavelength; triple wavelength LHR; triple wavelength in skin types 4-5.

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Hair
  • Hair Removal* / adverse effects
  • Humans
  • Laser Therapy*
  • Lasers, Semiconductor / adverse effects
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Young Adult